OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • December 30th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations • New York
2,750,498 SHARES ANAPTYSBIO, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • August 14th, 2024 • Anaptysbio, Inc • Pharmaceutical preparations • New York
INDEMNITY AGREEMENTIndemnity Agreement • September 9th, 2015 • Anaptysbio Inc • Pharmaceutical preparations • Delaware
This Indemnity Agreement, dated as of , 2015 is made by and between AnaptysBio, Inc., a Delaware corporation (the “Company”), and , a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
OFFICE LEASE KILROY REALTY PACIFIC CORPORATE CENTER KILROY REALTY, L.P., a Delaware limited partnership, as Landlord, andOffice Lease • December 23rd, 2015 • Anaptysbio Inc • Pharmaceutical preparations • California
This Office Lease (the “Lease”), dated as of the date (the “Effective Date”) set forth in Section l of the Summary of Basic Lease Information (the “Summary”), below, is made by and between KILROY REALTY, L.P., a Delaware limited partnership (“Landlord”), and ANAPTYSBIO, INC., a Delaware corporation (“Tenant”).
ANAPTYSBIO, INC. FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • September 9th, 2015 • Anaptysbio Inc • Pharmaceutical preparations • California
THIS FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of July 13, 2015 by and among ANAPTYSBIO, INC., a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
2,200,000 Shares ANAPTYSBIO, INC. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • September 26th, 2018 • Anaptysbio Inc • Pharmaceutical preparations • New York
2 - contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or 462(b) of the Securities Act, or...Common Stock Sales Agreement • November 8th, 2022 • Anaptysbio, Inc • Pharmaceutical preparations • New York
ANAPTYSBIO, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 5th, 2024 • Anaptysbio, Inc • Pharmaceutical preparations • New York
LEASE AGREEMENT BETWEENLease Agreement • May 6th, 2020 • Anaptysbio, Inc • Pharmaceutical preparations • California
THIS LEASE AGREEMENT (this “Lease”) is made as of May 4, 2020 (“Effective Date”), by and between WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (“Landlord”), and ANAPTYSBIO, INC., a Delaware corporation (“Tenant”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • July 17th, 2015 • Anaptysbio Inc • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of December 24, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and ANAPTYSBIO, INC., a Delaware corporation with offices located at 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (individually and collectively, jointly and severally, “Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall re
COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • May 10th, 2016 • Anaptysbio Inc • Pharmaceutical preparations • Delaware
This COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of March 10 , 2014 (the “Effective Date”), is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”).
ANAPTYSBIO, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of August 4, 2023 (the “Effective Date”), by and among ANAPTYSBIO, INC. (the “Company”) and Daniel Faga...Employment Agreement • November 2nd, 2023 • Anaptysbio, Inc • Pharmaceutical preparations • California
ANAPTYSBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2020 • Anaptysbio, Inc • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from July 15, 2020 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Dennis Mulroy (“CFO”). The Company and CFO are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.”
ANTIBODY GENERATION AGREEMENTAntibody Generation Agreement • December 28th, 2016 • Anaptysbio Inc • Pharmaceutical preparations • California
This ANTIBODY GENERATION AGREEMENT is entered into and effective as of December 2011 (the “Effective Date”), by and between ANAPTYSBIO, INC., a Delaware corporation (“AnaptysBio”), having its principal place of business at 10421 Pacific Center Court, Suite 200, San Diego, CA 92121, and CELGENE CORPORATION, a Delaware corporation (together with its subsidiaries and affiliates hereinafter collectively referred to as “Client”), having its principal place of business at 86 Morris Avenue, Summit, NJ 07901.
NON-EXCLUSIVE RESEARCH AND COMMERCIAL LICENSE AGREEMENTNon-Exclusive Research and Commercial License Agreement • August 18th, 2015 • Anaptysbio Inc • Pharmaceutical preparations
This Non-Exclusive Research and Commercial License Agreement (this “AGREEMENT”) is made by and between AnaptysBio, Inc. (“ANAPTYSBIO”), a Delaware corporation, with a principal business address at 10835 Road To The Cure, Suite 100, San Diego, CA 92121, and MILLIPORE CORPORATION (“MILLIPORE”), a Massachusetts corporation with offices at 290 Concord Road, Billerica, MA 91821, and is effective as of May 15, 2009 (the “EFFECTIVE DATE”). MILLIPORE and ANAPTYSBIO are sometimes each referred to herein individually as a “PARTY” and together as the “PARTIES”.
ANAPTYSBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 9th, 2015 • Anaptysbio Inc • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from October 20, 2014 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Marco Londei (“CDO”). The Company and CDO are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 17th, 2017 • Anaptysbio Inc • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of December 24, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and ANAPTYSBIO, INC., a Delaware corporation with offices located at 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (individually and collectively, jointly and severally, “Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall re
ANAPTYSBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2020 • Anaptysbio, Inc • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from July 31, 2020 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Paul Lizzul, MD (“CMO”). The Company and CMO are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.”
LICENSE AGREEMENT Between ANAPTYS BIOSCIENCES, INC. (ANAPTYS) and MEDICAL RESEARCH COUNCIL (MRC)License Agreement • September 9th, 2015 • Anaptysbio Inc • Pharmaceutical preparations • England
This Exclusive License Agreement (“Agreement”), is entered into as of the 30th day of August 2006 (hereinafter called “Effective Date”), by and between the MEDICAL RESEARCH COUNCIL (“MRC”), a UK government funded non-departmental body with principal offices at, 20 Park Crescent, London, W1B 1AL, United Kingdom and ANAPTYS BIOSCIENCES, INCORPORATED (“ANAPTYS”), a corporation organized under the laws of Delaware and having a principal place of business at 10931 North Torrey Pines Road, Suite 101, La Jolla, California 92037, United States of America.
ANAPTYSBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 28th, 2016 • Anaptysbio Inc • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from March 22, 2016 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Matthew Moyle (“CSO”). The Company and CSO are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
ContractLicense Agreement • May 9th, 2024 • Anaptysbio, Inc • Pharmaceutical preparations
TERMINATION OF SUBLEASETermination of Sublease • February 25th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations
THIS TERMINATION OF SUBLEASE (this "Agreement") is dated as of November 11, 2020, between TREX ENTERPRISES CORPORATION, a California corporation ("Sublessor"), and ANAPTYSBIO, INC., a Delaware Corporation (“Sublessee”) (collectively “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 8th, 2018 • Anaptysbio Inc • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from August 6, 2018 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Eric Loumeau (“GC”). The Company and GC are hereinafter collectively referred to as the “Parties,” and individually referred to as a “Party.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION COPY 1 LICENSE AGREEMENT THIS LICENSE...License Agreement • March 11th, 2024 • Anaptysbio, Inc • Pharmaceutical preparations • New York
CONSULTING AGREEMENTConsulting Agreement • September 9th, 2015 • Anaptysbio Inc • Pharmaceutical preparations • California
This Consulting Agreement (“Agreement”) is entered into as of May 1, 2015 (the “Effective Date”), between AnaptysBio, Inc. (“Company”), and David King (“Consultant”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMEMNT, MARKED BY [***], HAS BEEN OMITTED BECAUSE THE INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version PURCHASE AND...Purchase and Sale Agreement • November 8th, 2022 • Anaptysbio, Inc • Pharmaceutical preparations • New York
AMENDMENT NO. 3 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • February 25th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations
This Amendment No. 3 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of October 23, 2020 (the “Amendment Date”), is entered into is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO Collectively, AnaptysBio and TESARO are referred to as the “Parties” and, individually, as a “Party”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 5 TO COLLABORATION AND EXCLUSIVE LICENSE...Collaboration and Exclusive License Agreement • March 11th, 2024 • Anaptysbio, Inc • Pharmaceutical preparations
CONFIDENTIAL SETTLEMENT AND MODIFICATION AGREEMENTSettlement Agreement • February 25th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations • Delaware
This Confidential Settlement and Modification Agreement (the “Agreement”) is made and entered into on the date that it is signed by the last of the signatories identified below (the “Effective Date”), by and between (i) AnaptysBio, Inc., a Delaware corporation having its principal place of business at 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (“AnaptysBio”), (ii) Tesaro, Inc., a Delaware corporation having its principal place of business in 1000 Winter Street, Waltham, Massachusetts 02451, (iii) Tesaro Development, Ltd., a Bermuda corporation having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with Tesaro, Inc., “Tesaro”), and (iv) GlaxoSmithKline LLC, a Delaware limited liability corporation having its principal place of business at 5 Crescent Drive, Philadelphia, PA 19112 (“GSK”) (Tesaro and GSK, collectively, “Defendants”) (each individually the “Party” or collectively the “Parties”).
ANAPTYSBIO, INC. EMPLOYMENT AGREEEMENTEmployment Agreement • July 17th, 2015 • Anaptysbio Inc • Pharmaceutical preparations • California
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into effective as of January 1, 2012 (the “Effective Date”) by and among ANAPTYSBIO, INC. (the “Company”) and Hamza Suria (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND AMENDMENT NO. 1 TO THE ROYALTY PURCHASE...Royalty Purchase Agreement • August 5th, 2024 • Anaptysbio, Inc • Pharmaceutical preparations • New York
THIS AGREEMENT AND AMENDMENT NO. 1 (this “Amendment”) TO THE ROYALTY PURCHASE AGREEMENT, dated as of October 25, 2021 (the “Original Purchase Agreement”), is effective as of May 8, 2024 (the “Amendment Effective Date”) and is entered into by and between ANAPTYSBIO, INC., a Delaware corporation, as Seller (“Seller”), and SAGARD HEALTHCARE PARTNERS FUNDING BORROWER SPE 2, LP, a Delaware limited partnership (as assignee of Sagard Healthcare Partners (Delaware) II LP, a Delaware limited partnership, which was, in turn, assignee of Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership), as Purchaser (“Purchaser”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the respective meanings ascribed to them in the Original Purchase Agreement (including as may be as ascribed to them in the License Agreement), except as otherwise set forth in Sections 2, 5 and 6 of this Amendment.
AMENDMENT NO. 4 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • March 7th, 2022 • Anaptysbio, Inc • Pharmaceutical preparations
This Amendment No. 4 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of October 21, 2021 (the “Amendment Date”), is entered into by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”). Collectively, AnaptysBio and TESARO are referred to as the “Parties” and, individually, as a “Party”.
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • August 9th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO LEASE AGREEMENT (“Amendment”) is effective as of April 5, 2021 (“Amendment Effective Date”), by and between WATERIDGE PROPERTY OWNER, LP, a Delaware limited partnership (“Landlord”), and ANAPTYSBIO, INC., a Delaware corporation (“Tenant”), with reference to the facts set forth in the Recitals below.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE THE INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL Execution Version ROYALTY...Royalty Purchase Agreement • December 1st, 2021 • Anaptysbio, Inc • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 7th, 2018 • Anaptysbio Inc • Pharmaceutical preparations • Delaware
This Amendment No. 1 to Fourth Amended and Restated Investor Rights Agreement (this “Amendment”) is entered into as of May 8, 2018 by the undersigned parties to that certain Fourth Amended and Restated Investor Rights Agreement, dated as of July 13, 2015 (the “Rights Agreement”), by and among AnaptysBio, Inc., a Delaware corporation (the “Company”) and the Investors. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Rights Agreement.
